February 2019 Br J Cardiol 2019;26:12
BJC Staff
Non-inferior cardiovascular outcome for DPP-4 inhibitor Results from the CAROLINA cardiovascular outcome study show that the DPP-4 inhibitor linagliptin (Trajenta®, Boehringer Ingelheim and Eli Lilly) is non-inferior to the sulphonylurea glimepiride in the treatment of adults with type 2 diabetes and cardiovascular risk. The study met its primary end point – defined as the non-inferiority of linagliptin versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The study, carried out over six years in 6,033 adults with type 2 diabetes and increased cardiovascular risk or est
February 2016 Br J Cardiol 2016;23:(1) doi:10.5837/bjc.2016.001
Peter Currie
(more…)
March 2014 Br J Cardiol 2014;21:8
Nigel I Jowett
Echocardiography and enlarged cardiothoracic ratio Dear Sirs, The Guys’ and St Thomas’s echo team are to be congratulated on producing evidence-based advice that could result in a significant reduction in cardiac ultrasound referrals, which may be enhanced if our radiology colleagues are taken on board.1 Many years ago, our echo department was overloaded with requests for studies as a consequence of radiology reports that included the emotive term ‘cardiomegaly’. This expression is, of course, speculative, as enlargement of the ‘cardiac’ shadow may be due to an expiratory radiograph, prominent epicardial fat pads, pericardial effu
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits